A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol

Hepatology International

Volumn 6, Issue 2, 2012, Pages 441-448

  Xie, Wen ^a   Shi, Guangfeng ^b   Zhang, Hongfei ^c   Zhao, Guiming ^d   Yu, Zujiang ^e   Lang, Zhenwei ^a   Zhao, Hong ^a   Yan, Jie ^a   Cheng, Jun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c BEIJING 302 HOSPITAL   (China)

^d Tianjin Infectious Disease Hospital   (China)

^e ZHENGZHOU UNIVERSITY   (China)

Author keywords

Adefovir dipivoxil; Bicyclol; Chronic hepatitis B

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BICYCLOL; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LIVER PROTECTIVE AGENT; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; FEMALE; GINGIVA BLEEDING; HEPATITIS B; HUMAN; INSOMNIA; LEG PAIN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; TREATMENT DURATION;

EID: 84862882332     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9294-7     Document Type: Article

References (32)

1. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38:S158-S168
2. Mendy ME, Welzel T, Lesi OA, et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 2010;17:115-122
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45: 507-539
4. Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-295
5. Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a metaanalysis. J Natl Cancer Inst 2009;101:1066-1082
6. Sylvan SP, Hellstrom UB. Modulation of serum interleukin-18 concentrations and hepatitis B virus DNA levels during interferon therapy in patients with hepatitis B e-antigen-positive chronic hepatitis B. J Interferon Cytokine Res 2010;30:901-908
7. Wolters LM, Niesters HG, de Man RA, et al. Nucleoside analogues for chronic hepatitis B. Eur J Gastroenterol Hepatol 2001;13:1499-1506
8. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health 2010;13:922-933
9. Schif ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 2003;38:1419-1427
10. Marcellin P, Cadranel JF, Fontanges T, et al. High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients. Eur J Gastroenterol Hepatol 2010;22:1290-1296
11. Upadhyaya N, Chang R, Davis C, et al. Chronic hepatitis B: perceptions in Asian American communities and diagnosis and management practices among primary care physicians. Postgrad Med 2010;122:165-175
12. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893
13. Tak WY, Park SY, Cho CM, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010;53:261-266
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681
15. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816
16. Ryu HJ, Lee JM, Ahn SH, et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2010;82:1835-1842
17. Freedman ND, Curto TM, Morishima C, et al. Silymarin use and liver disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Aliment Pharmacol Ther 2011;33:127-137
18. Lin A, Chen J, Liu Y, et al. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm 2009;35: 1348-1355
19. Liu GT, Li Y, Wei HL, et al. Mechanism of protective action of bicyclol against CCl4-induced liver injury in mice. Liver Int 2005;25:872-879
20. Bao XQ, Liu GT. Involvement of HSP70 in the protection of bicyclol on apoptosis of HepG2 cells intoxicated by D-galactosamine. J Asian Nat Prod Res 12:313-323
21. Lou XE, Xu N, Yao HP, et al. Bicyclol attenuates pro-inflammatory cytokine and chemokine productions in CpG-DNAstimulated L02 hepatocytes by inhibiting p65-NF-kappaB and p38-MAPK activation. Pharmazie 2010;65:206-212
22. Yu YN, Chen H, Li Y. Effect of bicyclol on cisplatin-induced hepatotoxicity in the hepatocarcinoma 22 tumour-bearing mice. Basic Clin Pharmacol Toxicol 2009;104:300-305
23. Bao XQ, Liu GT. Induction of overexpression of the 27-and 70-kDa heat shock proteins by bicyclol attenuates concanavalin A-induced liver injury through suppression of nuclear factorkappaB in mice. Mol Pharmacol 2009;75:1180-1188
24. Sun H, Liu GT. Inhibitory effect of anti-hepatitis drug bicyclol on invasion of human hepatocellular carcinoma MHCC97-H cells with high metastasis potential and its relative mechanisms. J Asian Nat Prod Res 2009;11:576-583
25. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435
26. Westland CE, Yang H, Delaney WE, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepatitis 2005;12:67-73
27. Minde Z, Yimin M, Guangbi Y, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg positive chronic hepatitis B. Hepatology 2006;43:108-116
28. Kim HJ, Park JH, Park DI, et al. Rescue therapy for lamivudineresistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2006;25: 1374-1380
29. Li M, Liu GT. Inhibition of Fas/FasL mRNA expression and TNF-a release in concanavalin A-induced liver injury in mice by bicyclol. World J Gastroenterol 2004;10:1775-1779
30. Liu GT. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. Med Chem 2009;5:29-43
31. Liu Geng Tao. Bicyclol: A novel drug for treating chronic viral hepatitis B and C. Med Chem 2009;5:29-43
32. Bao XQ, Liu GT. Bicyclol protects HepG2 cells against Dgalactosamine-induced apoptosis through inducing heat shock protein 27 and mitochondria associated pathway. Acta Pharmacol Sin 2010;31:219-226